Zacks Investment Research : declared in Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Inovio (NASDAQ: INO)'s HIV Vaccine Elicits High Response Rates In Phase 1 Trial

Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. VGX-3100, the firm noted, would be the first candidate within the company's extensive pipeline to enter a pivotal study. The analysts noted that the goal of development is to attain long-term HIV remission in the absence of antiviral drugs. However, the firm believes further studies need to be conducted to find whether Pennvax-GP can safely and effectively prevent HIV infection. As such, the firm reiterated its Buy rating and $13 price target on the facebook/" target="_blank">shares of Inovio Pharma.


What happenedShares of the clinical-stage biotech Inovio Pharmaceuticals (NASDAQ:INO) gained as much as 38% today due to a positive early-stage readout for its experimental HIV vaccine called Pennvax-GP. Now whatBefore investors get too excited, though, it's important to remember that this HIV vaccine is years away from even a possible regulatory filing. So whatAn effective and safe HIV vaccine that can prevent and/or cure patients would easily generate billions in sales in short order. In other words, Inovio may be able to monetize this promising clinical asset sooner, rather than later. The long and short of it is that this experimental HIV vaccine just produced some of the strongest immune responses ever observed in a human clinical trial, according to Inovio.


collected by :Lucy William

To follow all the new news about Health care